Synthetica

Unlocking Hematologic Disease Patterns: Inside the ASH HematOmics Program

Lu C, Matt GY, Paul R, et al.•5 min read•Impact Score: 50
50Impact
View Original Paper
Executive Summary
  • ASHOP aggregates genomic, transcriptomic, and clinical data from 5,960 patients across five major hematologic malignancies.
  • Features interactive visualization tools for mutation landscapes, UMAP transcriptomic clustering, and survival modeling.
  • Demonstrates four major clinical use cases, including novel DUX4-rearranged B-ALL subtyping and TP53 alteration profiling.

Unlocking Hematologic Disease Patterns: Inside the ASH HematOmics Program

Modern cancer research relies heavily on next-generation sequencing, yet integrating complex multi-omics data with real-world patient outcomes remains a significant challenge. To address this, the American Society of Hematology introduced the ASH HematOmics Program (ASHOP)—a centralized, open-access platform designed to streamline integrative analysis for hematologic diseases.

A Unified Multi-Omics Ecosystem

ASHOP brings together high-throughput genomic and transcriptomic sequencing with rich clinical histories. The initial platform release covers 5,960 patients spanning five major hematologic conditions:

  • Acute Myeloid Leukemia (AML)
  • B-cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
  • T-cell Acute Lymphoblastic Leukemia (T-ALL)
  • Myelodysplastic Syndromes (MDS)
  • Chronic Lymphocytic Leukemia (CLL)

By democratizing access to interactive data tools, ASHOP allows researchers to explore alteration landscapes, co-mutation profiles, and transcriptomic signatures without requiring complex local bioinformatics pipelines.

Powerful Analytical Capabilities

ASHOP equips researchers with intuitive web-based visual analytics:

  1. Mutational Profiling: Examine somatic alterations and gene fusions using interactive lollipop plots and comutation matrices across user-defined patient subcohorts.
  2. Transcriptomic Visualizations: Navigate single-cell and bulk RNA-seq data via UMAP projections, cluster identification, differential expression analysis, and pathway enrichment.
  3. Clinical Correlations: Link transcriptomic features and genetic variants directly to patient outcomes and survival metrics.

Real-World Impact: Four Key Use Cases

To demonstrate ASHOP's utility, the research team highlighted four critical clinical applications:

  1. DUX4-Rearranged B-ALL Stratification: Stratified patient cohorts into Early/Multipotent and Committed subgroups, revealing distinct clinical outcomes.
  2. HOX Gene Architecture: Mapped intricate HOXA and HOXB expression patterns across acute myeloid leukemias.
  3. Mutational Load & Repair: Correlated tumor mutational burden with mismatch repair deficiencies and specific mutational signatures.
  4. TP53 Architecture: Dissected the complex alteration landscape of the TP53 tumor suppressor across multiple blood cancers.

Looking Ahead

ASHOP marks a giant leap forward for open-science oncology platforms. As the ASH community continues to expand this resource with additional clinical datasets and disease categories, ASHOP promises to accelerate precision diagnostics and novel therapeutic discoveries across hematology.